Newer agents in antiplatelet therapy: a review
Explore this paper's citation graph
Summary
The validation and search for newer antiplatelet therapeutic approaches proven to be superior to aspirin is still ongoing and should yield a better pharmacodynamic profile with fewer untoward side-effects to what is currently in use today.
- Type
- article
- Published
- 2012-06-01
- Cited by
- 61
- References
- 116
- Access
- Open access
- OpenAlex
- https://openalex.org/W22792011
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4823241
Keywords
Computer science
References
- EUROPEAN STROKE PREVENTION STUDY 2: DIPYRIDAMOLE AND ACETYLSALICYLIC ACID IN THE SECONDARY PREVENTION OF STROKE
- Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y12 receptor inhibitor
- Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.
- Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT
- Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines
- Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
- A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase.
- Fibrinogen-binding properties of the human platelet glycoprotein IIb-=IIIa complex: a study using crossed-radioimmunoelectrophoresis.
- Isolation and characterization of a collagen binding domain in human von Willebrand factor.
- EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION
- Effect of ticlopidine ex vivo on platelet intracellular calcium mobilization.
- Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri.
- Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets.
- Identification and Biological Activity of the Active Metabolite of Clopidogrel
- Ticlopidine and clopidogrel.
- Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease.
- Pharmacodynamics and Pharmacokinetics of Higher-Dose, Double-Bolus Eptifibatide in Percutaneous Coronary Intervention
- A new oral antiplatelet agent with potent antithrombotic properties: Comparison of DZ-697b with clopidogrel in a randomised phase I study
- Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
- A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice.
Cited by
- Platelet Responses in Cardiovascular Disease: Sex-Related Differences in Nutritional and Pharmacological Interventions
- Nachweis Thrombozyten-induzierter Apoptose und therapeutische Konsequenzen
- Pannexin-1 and other anion channels in platelets and megakaryocytes
- Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence
- Vanilloid‐Like Agents: Potential Therapeutic Targeting of Platelets?
- Contribution of blood platelets to vascular pathology in Alzheimer’s disease
- Vipegitide: a folded peptidomimetic partial antagonist of α2β1 integrin with antiplatelet aggregation activity
- Discovery of Novel GPVI Receptor Antagonists by Structure-Based Repurposing
- Pharmacokinetics and tissue distribution study of novel potent antiplatelet agent S007-867 in mice using HPLC-MS/MS
- Dietary manipulation of platelet function.
- The emerging role of oxylipins in thrombosis and diabetes
- Structural insights into the extra cellular segment of integrinβ5 and molecular interaction studies
- Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer’s disease
- A Sticky Story for Signal Transducer and Activator of Transcription 3 in Platelets
- Dual antiplatelet therapy for PCI: Are we tailored to all?
- Cilostazol enhances endothelium-dependent vasodilatation of intact endothelium in isolated rat aortic rings Silostazol izole siçan aort halkalarinda sağlam endotelin endotel bağimli vazodilatasyonunu artirir
- Insight into interactions between aspirin and non- steriodal anti-inflammatory drugs
- Thromboembolic events secondary to tirofiban-induced thrombocytopenia being treated with thrombopoietin: A case report.
- Novel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis
- Development of Poly Unsaturated Fatty Acid Derivatives of Aspirin for Inhibition of Platelet Function
Related papers
No related papers recorded.